Navigation Links
Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Date:5/28/2008

ProLindac Demonstrates Sustained and Significant Reductions in Cancer

Market CA-125

DALLAS, May 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that the company gave an invited oral presentation on its lead anticancer compound, ProLindac(TM) at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice, taking place from May 26-28 in Valencia, Spain. The presentation was entitled "Promising Safety and Efficacy Results from an Ongoing Clinical Study of ProLindac in Recurrent Ovarian Cancer." ProLindac is Access' novel DACH platinum-polymer prodrug, which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials.

The invited presentation was given by Professor Esteban Cvitkovic, M.D., Access Pharmaceuticals' Senior Director, Clinical Oncology R&D. Professor Cvitkovic presented data from the ongoing Phase 2 monotherapy clinical study of ProLindac in patients with recurrent ovarian cancer. In two dosing regimens, ProLindac was given once every two weeks and once every three weeks. During the last and highest dose levels explored, sustained and significant reductions in the specific serum market Ca-125 were seen over multiple dosings in several patients. ProLindac was well-tolerated with minimal side-effects.

"We continue to be impressed by clinical results that indicate a significant DACH platinum drug effect with a very benign side effect profile," stated Jeffrey B. Davis, Access' President & CEO. "The sustained efficacy and minimal toxicity seen over multiple dosings provides further evidence that ProLindac has the potential to become a very important anticancer agent in the future. We are finalizing our plans for Phase 2 combination trials where we intend to look at multiple solid tumor types with ProLindac in combination with other cancer agents, like taxol and gemcitabine."


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
2. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
10. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
(Date:4/18/2014)... new medical-testing device is being prepped to enter ... improve diagnosis of certain diseases in remote areas, ... series of investigations aboard the International Space Station ... the space-tested concept of capillary flow to diagnose ... David Kelso, Ph.D., a researcher at Northwestern University ...
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... made a brain-related discovery that could revolutionize doctors, ... discovery opens up the possibility that environmental and/or ... brain activity that the researchers have identified as ... of Neuroscience has just published a paper ... professor of psychology and his doctoral student John ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Decreased muscle strength is associated with difficulty in ... kneeling (SCK) in older adults, according to an ... Physical Therapy (PTJ), the scientific journal ... researchers found that adults with SCK difficulty had ...
... They differ from each other in many ways, and they ... HIV to resist a host of weapons fired at ... emerging. One potential weapon is a small-molecule ... by attacking them through some feature common to an entire ...
... ... a Soho Seminar event that will help you transform the way employees engage inside and ... ... at the Soho Seminars event “Aligning the Corporate and Personal Brand,” hosted by Loyola ...
... effect on heart from androgen deprivation, official says ... with prostate cancer and the physicians who treat ... (ADT) commonly used against the malignancy might increase ... , "There is a substantial amount of data ...
... , PHILADELPHIA , ... GlaxoSmithKline plc will announce its full year financial results for the ... the announcement will be released to the London Stock Exchange at ... www.gsk.com . , Following the announcement, Andrew Witty , ...
... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
Cached Medicine News:Health News:Decreased muscle strength predicts functional impairments in older adults 2Health News:Decreased muscle strength predicts functional impairments in older adults 3Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 2Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 3Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:GSK 2009 Financial Results Announcement and Teleconference Details 2Health News:FDA Announces Safety Risk Associated with HIV Drug 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: